Highlight
- This chemotherapy-free regimen in untreated indolent B-cell NHL achieves an 86% complete response rate by PET-CT.
- Frontline single-agent mosunetuzumab yields a 71% complete response rate, while response-adapted polatuzumab vedotin plus obinutuzumab salvages non-CR patients effectively.
- The 2-year progression-free survival reaches 89%, with minimal high-grade toxicity and manageable cytokine release syndrome limited to grade 1.
- This approach offers a promising personalized treatment template balancing efficacy and safety, potentially transforming frontline management of follicular and marginal zone lymphoma.
Specialty calculators
For clinical reference; use professional judgment.

